Kiniksa Pharmaceuticals International, plc
KNSA
Rank in Stocks
#2964
Kiniksa Pharmaceuticals International, plc, a biopharmaceutical company,... Kiniksa Pharmaceuticals International, plc, a biopharmaceutical company, develops and commercializes medical therapies in the United States, the United Kingdom, and internationally. The company offers ARCALYST, an interleukin-1alpha and 1beta cytokine trap for the treatment of recurrent pericarditis, a chronic autoinflammatory cardiovascular disease and cardiac sarcoidosis. It also develops KPL-387, an investigational and fully human immunoglobulin G2 monoclonal antibody, which is Phase 2/3 clinical trial for the treatment of recurrent pericarditis; and KPL-116, a Fc-modified immunoglobulin G2 monoclonal antibody, which is in pre-clinical stage. The company was formerly known as Kiniksa Pharmaceuticals, Ltd. and changed its name to Kiniksa Pharmaceuticals International, plc in June 2024. Kiniksa Pharmaceuticals International, plc was incorporated in 2015 and is based in London, the United Kingdom.
Share Price
$79.61
Last synced: 2026-10-19
Market Cap
$6.21B
Change (1 day)
1.30%
Change (1 year)
104.18%
Country
GB
Trade Kiniksa Pharmaceuticals International, plc (KNSA)
Category
Healthcare
P/E ratio for Kiniksa Pharmaceuticals International, plc (KNSA)
P/E ratio as of October 2026 TTM: 73.68
According to Kiniksa Pharmaceuticals International, plc latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is 73.68. At the end of 2023 the company had a P/E ratio of 87.25.
P/E ratio history for Kiniksa Pharmaceuticals International, plc from 2016 to 2026
P/E ratio at the end of each year
| Year | P/E Ratio | Change |
|---|---|---|
| 2026 (TTM) | 73.68 | -325.26% |
| 2024 | -32.71 | -137.49% |
| 2023 | 87.25 | 1,439.30% |
| 2022 | 5.67 | -210.90% |
| 2021 | -5.11 | -24.52% |
| 2020 | -6.77 | 83.35% |
| 2019 | -3.69 | -54.07% |
| 2018 | -8.04 | -17.48% |
| 2017 | -9.74 | -63.05% |
| 2016 | -26.37 | 0.00% |
P/E ratio for similar companies or competitors
| Company | P/E Ratio | P/E Ratio Difference | Country |
|---|---|---|---|
| 24.47 | -66.79% |
US
|
|
| - | - |
SE
|
|
| - | - |
FR
|
|
| - | - |
IT
|
|
| 33.58 | -54.42% |
HK
|
How to read a P/E ratio?
The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share.
A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.
Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.